TRVITrevi Therapeutics, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Oversold (RSI 27). Price is −5% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How TRVI is trading
Trevi Therapeutics, Inc. is +62% over the past year while the S&P 500 is +18%: 44 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −5.3%
vs 200-day average · below trend, but not far
- RSI (14)
- 27
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 31%
Below its 52-week high
Details›
- Last close2026-10-09
- $13.20
- 1 monthS&P 500 +2.7%
- −17%
- 1 yearS&P 500 +18%
- +62%
- 5 yearsS&P 500 +88%
- +830%
- vs 50-day average$16.37
- −19%
- 52-week high
- $19.07
- 52-week low
- $8.38
- Annualised volatility
- 74%
| Year | Return |
|---|---|
| 2026 (year to date) | +5.4% |
| 2025 | +204% |
| 2024 | +207% |
| 2023 | −31% |
| 2022 | +147% |
| 2021 | −68% |
| 2020 | −35% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 4 of 7 | +6.2% |
| Feb | 7 | 6 of 7 | +19% |
| Mar | 7 | 4 of 7 | +34% |
| Apr | 7 | 4 of 7 | +13% |
| May | 7 | 1 of 7 | −11% |
| Jun | 8 | 6 of 8 | +22% |
| Jul | 8 | 4 of 8 | −0.86% |
| Aug | 8 | 1 of 8 | −8.1% |
| Sep | 8 | 2 of 8 | −7.5% |
| Oct | 8 | 2 of 8 | −6.6% |
| Nov | 7 | 2 of 7 | −4.6% |
| Dec | 7 | 4 of 7 | +3.5% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.